Search

Search Results
Results 4671 - 4680 of 4752 for multiple sclerosis
  • Elan first quarter total revenue increases 17% to $288.4 million
    News - 26 Apr 2012
    Elan Corporation, plc, today reported its first quarter 2012 financial results.
  • GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009
    News - 12 Mar 2010
    GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per...
  • Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009
    News - 23 Feb 2010
    Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.
  • Crestor
    Drug - 21 Jan 2026
    Consumer Medicine Information (CMI) about Crestor intended for persons living in Australia.
  • Remicade
    Drug - 21 Jan 2026
    Consumer Medicine Information (CMI) about Remicade intended for persons living in Australia.
  • Actemra
    Drug - 16 Jan 2026
    Consumer Medicine Information (CMI) about Actemra intended for persons living in Australia.
  • Ixifi
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Ixifi intended for persons living in Australia.
  • Simponi
    Drug - 11 Dec 2025
    Consumer Medicine Information (CMI) about Simponi intended for persons living in Australia.
  • Dapa-Tabs
    Drug - 10 Dec 2025
    Consumer Medicine Information (CMI) about Dapa-Tabs intended for persons living in Australia.
  • Perisyl Combi
    Drug - 9 Dec 2025
    Consumer Medicine Information (CMI) about Perisyl Combi intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback